Aoli Wang

3.1k citations

62 papers · 2.0k · 2 hit papers · h-index 18

Impact in

Nephrology top 2%
- Gout, Hyperuricemia, Uric Acid
Biological Psychiatry top 5%

Papers in

Molecular Biology 37
- PI3K/AKT/mTOR signaling in cancer 6
- Histone Deacetylase Inhibitors Research 4
Hematology 13
- Chronic Myeloid Leukemia Treatments 8
- Acute Myeloid Leukemia Research 4

Co-authors: Qingsong Liu (41 shared papers)Rongbin Zhou (2 shared papers)Chao Wang (2 shared papers)Wei Jiang (2 shared papers)Xianming Deng (2 shared papers)Hongbin He (2 shared papers)Hua Jiang (1 shared paper)Jin Ye (1 shared paper)
Journals: Journal of Medicinal Chemistry (14 papers)European Journal of Medicinal Chemistry (9 papers)Acta Pharmacologica Sinica (5 papers)Signal Transduction and Targeted Therapy (3 papers)Experimental Cell Research (3 papers)
Partner nations: China United States Japan

In The Last Decade

Aoli Wang

59 papers receiving 2.0k citations

Aoli Wang's Hit Papers

align trajectories log scale

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity 2018 · 633 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Nature Communications
2017 The Journal of Experimental Medicine

Peers

Countries citing papers authored by Aoli Wang

Since Specialization

Citations

This map shows the geographic impact of Aoli Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aoli Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aoli Wang more than expected).

Fields of papers citing papers by Aoli Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aoli Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aoli Wang. The network helps show where Aoli Wang may publish in the future.

Co-authors

The 25 scholars most cited alongside Aoli Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aoli Wang Line = papers co-authored together Aoli Wang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity Nature Communications ·Hongbin He, Hua Jiang, Yun Chen, Jin Ye, Aoli Wang, Chao Wang, Qingsong Liu, Gaolin Liang, Xianming Deng, Wei Jiang, Rongbin Zhou Hit paper breakdown →	2018	633
2	Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders The Journal of Experimental Medicine ·Hua Jiang, Hongbin He, Yun Chen, Wei Huang, Jinbo Cheng, Jin Ye, Aoli Wang, Jin‐Hui Tao, Chao Wang, Qingsong Liu, Tengchuan Jin, Wei Jiang, Xianming Deng, Rongbin Zhou Hit paper breakdown →	2017	611
3	Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC European Journal of Medicinal Chemistry ·Yongfei Chen, Jiaxin Wu, Aoli Wang, Ziping Qi, Taoshan Jiang, Chen Cheng, Fengming Zou, Chen Hu, Wei Wang, Wu Hong, Zhenquan Hu, Wenchao Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Qingsong Liu, Jing Liu	2017	55
4	Variation of gut microbiota caused by an imbalance diet is detrimental to bugs' survival The Science of The Total Environment ·Jing Luo, Yanxia Cheng, Libin Guo, Aoli Wang, Min Lu, Letian Xu	2021	55
5	Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52 Acta Pharmacologica Sinica ·Wenliang Wang, Zongru Jiang, Chen Hu, Cheng Chen, Zhenquan Hu, Aoli Wang, Li Wang, Jing Liu, Wenchao Wang, Qingsong Liu	2020	33
6	Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent Acta Pharmaceutica Sinica B ·Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong, Wenchao Wang, Qingsong Liu	2019	29
7	Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode Journal of Medicinal Chemistry ·Aoli Wang, Xixiang Li, Hong Wu, Fengming Zou, Xiao-E Yan, Chen Cheng, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai‐Hong Yun, Jing Liu, Qingsong Liu	2017	28
8	Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway Acta Pharmacologica Sinica ·Cheng Chen, Chuan-dong Cheng, Hong Wu, Zuowei Wang, Li Wang, Zongru Jiang, Aoli Wang, Chen Hu, Yongfei Dong, Wanxiang Niu, Shuang Qi, Ziping Qi, Jing Liu, Wenchao Wang, Chaoshi Niu, Qingsong Liu	2020	26
9	Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia Journal of Medicinal Chemistry ·Xixiang Li, Aoli Wang, Kailin Yu, Ziping Qi, Cheng Chen, Wenchao Wang, Hu Chen, Wu Hong, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Lı Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu, Qingsong Liu	2015	26
10	Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies Signal Transduction and Targeted Therapy ·Husheng Mei, Hong Wu, Jing Yang, Bin Zhou, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu, Yongfei Chen, Wenchao Wang, Jing Liu, Qingsong Liu	2023	23
11	Cytotoxic clerodane furanoditerpenoids from the root of Tinospora sagittata Phytochemistry Letters ·Ningbo Qin, Aoli Wang, Dahong Li, Kai‐Bo Wang, Bin Lin, Zhan‐Lin Li, Huiming Hua	2015	21
12	Decreased nuclear stiffness via FAK-ERK1/2 signaling is necessary for osteopontin-promoted migration of bone marrow-derived mesenchymal stem cells Experimental Cell Research ·Lingling Liu, Qing Luo, Jinghui Sun, Aoli Wang, Yisong Shi, Yang Ju, Yasuyuki MORITA, Guanbin Song	2017	20
13	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors Journal of Medicinal Chemistry ·Yu Xue, Peiran Song, Zilan Song, Aoli Wang, Linjiang Tong, Meiyu Geng, Jian Ding, Qingsong Liu, Li‐Ping Sun, Hua Xie, Ao Zhang	2018	20
14	Salviachinensines A–F, Antiproliferative Phenolic Derivatives from the Chinese Medicinal PlantSalvia chinensis Journal of Natural Products ·Qi Wang, Zhenquan Hu, Xixiang Li, Aoli Wang, Wu Hong, Jing Liu, Shugeng Cao, Qingsong Liu	2018	20
15	Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas Journal of Medicinal Chemistry ·Bin Zhou, Xiaofei Liang, Husheng Mei, Shuang Qi, Zongru Jiang, Aoli Wang, Fengming Zou, Qingwang Liu, Juan Liu, Wenliang Wang, Chen Hu, Yongfei Chen, Zuowei Wang, Beilei Wang, Li Wang, (unknown), (unknown), Qingsong Liu	2021	19
16	Insights into the molecular recognition of the granuphilin C2A domain with PI(4,5)P2 Chemistry and Physics of Lipids ·Chanjuan Wan, Bo Wu, Zhenwei Song, Jiahai Zhang, Huiying Chu, Aoli Wang, Qingsong Liu, Yunyu Shi, Guohui Li, Junfeng Wang	2015	18
17	Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor European Journal of Medicinal Chemistry ·Qianmao Liang, Yongfei Chen, Kailin Yu, Cheng Chen, Shouxiang Zhang, Aoli Wang, Wei Wang, Wu Hong, Xiaochuan Liu, Beilei Wang, Li Wang, Zhenquan Hu, Wenchao Wang, Tao Ren, Shanchun Zhang, Qingsong Liu, Cai‐Hong Yun, Jing Liu	2017	18
18	Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy Acta Pharmaceutica Sinica B ·Chen Hu, Lijuan Shen, Fengming Zou, Yun Wu, Beilei Wang, Aoli Wang, Chao Wu, Li Wang, Jing Liu, Wenchao Wang, Qingsong Liu	2023	17
19	Discovery of a Highly Selective STK16 Kinase Inhibitor ACS Chemical Biology ·Feiyang Liu, Jinhua Wang, Xingxing Yang, Binhua Li, Hong Wu, Shuang Qi, Cheng Chen, Xiaochuan Liu, Kailin Yu, Wenchao Wang, Zheng Zhao, Aoli Wang, Yongfei Chen, Lı Wang, Nathanael S. Gray, Jing Liu, Xin Zhang, Qingsong Liu	2016	17
20	Positive feedback loops between fibroblasts and the mechanical environment contribute to dermal fibrosis Matrix Biology ·Liang Zhu, Lechen Liu, Aoli Wang, Jinwen Liu, Xin Huang, Tao Zan	2023	17

About Aoli Wang

Aoli Wang is a scholar working on Molecular Biology, Hematology, Genetics, Oncology and Pulmonary and Respiratory Medicine, having authored 62 papers that have together received 2.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (8 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Hippo pathway signaling and YAP/TAZ (5 papers), Gastrointestinal Tumor Research and Treatment (5 papers), HER2/EGFR in Cancer Research (4 papers), Acute Myeloid Leukemia Research (4 papers) and Histone Deacetylase Inhibitors Research (4 papers). The work is most often cited by research in Nephrology (233 citations), Biological Psychiatry (67 citations), Molecular Biology (1.4k citations), Immunology (339 citations) and Hematology (131 citations). Aoli Wang has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Qingsong Liu, Rongbin Zhou, Chao Wang, Wei Jiang, Xianming Deng, Hongbin He, Hua Jiang, Jin Ye, Gaolin Liang and Yun Chen. Their work appears in journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Acta Pharmacologica Sinica, Signal Transduction and Targeted Therapy and Experimental Cell Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Aoli Wang

Impact in

Papers in i

In The Last Decade

Aoli Wang

Aoli Wang's Hit Papers

Peers

Countries citing papers authored by Aoli Wang

Fields of papers citing papers by Aoli Wang

All Works

About Aoli Wang

Explore authors with similar magnitude of impact

Papers in